MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "1-Methyl-4-phenylpyridinium (MPP+)"

  • 2019 International Congress

    Protective effect of anodal transcranial direct current stimulation on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice via modulating mitochondrial dynamics

    W. Jang, JY. Ahn (Gangneung, Republic of Korea)

    Objective: The present study elucidated the neuroprotective effects of tDCS on the mitochondrial quality control pathway in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model. Background: Abnormal…
  • 2019 International Congress

    Hydralazine protects nigrostriatal dopaminergic neurons from MPP+ and MPTP induced neurotoxicity: Roles of Nrf2-ARE signaling pathway

    XF. Guo, T. Wang, J. Huang, N. Xiong, C. Han, K. Ma, Y. Xia, F. Wan, JJ. Hu, SJ. Yin, L. Kou, YD. Sun, JW. Wu (Wuhan, China)

    Objective: In this study, we tested whether hydralazine can attenuate 1-Methyl-4-phenylpyridinium (MPP+) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- induced neurotoxicity in vitro and in vivo by activating Nrf2…
  • 2019 International Congress

    Inhibition of mitochondrial complexes induces unique transcriptomic and epigenetic profiles: implications to neurodegeneration induced movement disorders

    R. Sathyanarayanan, S. Bharath (Bangalore, India)

    Objective: To compare the neurotoxicological hallmarks induced by inhibitors of mitochondrial complex I (CI- 1- methyl-4- phenylpyridinium; MPP+), complex II (CII- 3- nitropropionic acid; 3-…
  • 2019 International Congress

    THE EXPRESSION OF INOS IN MOUSE EXPERIMENTAL MODEL POINTS TO INFLAMMATORY CONDITIONS ASSOCIATED WITH PARKINSON’S DISEASE

    N. Djebli (Mostaganem, Algeria)

    Objective: The objective of conducting this study was to evaluate the expression of iNOS in mouse experimental model of PD. Background: Parkinson’s Disease (PD) is…
  • 2019 International Congress

    Beneficial and protective effects of Terminalia chebula in a murine model of Parkinson’s disease

    A. Kumar, S. Farhat (New Delhi, India)

    Objective: Present study was designed to investigate whether Terminalia chebula (TC) extract would prevent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)  induced neurotoxicity in male Wistar rats. Background: Parkinson's disease (PD)…
  • 2019 International Congress

    Increased vesicular monoamine transporter alleviate MPTP-induced impairment of neurogenesis

    K. Ma, G. Zhang, C. Han, X. Guo, Y. Xia, F. Wan, L. Kou, S. Yin, L. Liu, N. Xiong, J. Huang, T. Wang (Wuhan, China)

    Objective: In this study, we employed vesicular monoamine transporter 2–overexpressing mice (VMAT2-HI) to investigate the influence of increased vesicular storage of catacholamines on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced…
  • 2019 International Congress

    Improving neuroprotective effects of resveratrol by brain targeting through chitosan glutamate nanoparticles in MPTP induced parkinsonism

    M-R. Rahman, V-K. Kumar (Allahabad, India)

    Objective: The aim of the present study was to develop and evaluate the neuroprotective effects of resveratrol (RV) using chitosan glutamate nanoparticles (RV-CG-NPs) in a…
  • 2019 International Congress

    Apigenin loaded Phospholipid based nanoemulsion in Therapeutics of Parkinson’s Disease Via Attenuation of Oxidative Stress and Upregulation of Dopamine.

    M-R. Rahman, V-K. Kumar (Allahabad, India)

    Objective: The aim of the present study was to develop, optimizes and evaluate the antiparkinson effects of apigenin loaded phospholipid based nanoemulsion via attenuation of…
  • 2019 International Congress

    The Nigeria Parkinson Disease Registry

    O. Ojo, S. Abubakar, K. Wahab, O. Olugbo, E. Nwazor, O. Oshinaike, A. Bello, U. Williams, O. Ekenze, N. Okubadejo, NPD. Collaborators (Idi-Araba, Nigeria)

    Objective: To describe the methodology and preliminary baseline data from the Nigeria Parkinson Disease Registry (NPDR). Background: Disease registries offer an opportunity to expand the…
  • 2018 International Congress

    Oral treatment with sphingosine-1-phosphate receptors modulator prevents Parkinson symptoms concomitantly to reduced brain inflammation in MPTP mouse models

    M. Cyr, E. Pépin, G. Massicotte (Trois-Rivieres, QC, Canada)

    Objective: Here we explore the efficacy of an oral treatment with Fingolimod (FTY720), a selective sphingosine-1-phosphate receptors modulator, to prevent MPTP induced nigrostriatal loss and…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley